Vibrato Medical

Executive Summary

Vibrato Medical is developing a first-in-class noninvasive wearable therapeutic ultrasound device for critical limb ischemia (CLI) and peripheral arterial disease (PAD). The technology leverages decades of research to promote vasodilation and angiogenesis, improving tissue perfusion and potentially reducing amputations. The device addresses a significant unmet need in a large patient population, with no currently approved noninvasive treatment that promotes vessel growth. As a private company, Vibrato is likely in preclinical or early clinical stages, focusing on safety and efficacy data to support regulatory clearance. The market opportunity is substantial, and the innovative approach could disrupt the standard of care for CLI/PAD if clinical validation is achieved.

Upcoming Catalysts (preview)

• Q4 2026Clinical trial initiation for CLI75% success
• Q3 2026FDA Breakthrough Device designation50% success
• Q2 2026Series B funding round60% success